Christoph Hotzy
Medical University of Vienna
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christoph Hotzy.
American Journal of Human Genetics | 2011
Alexander Zimprich; Anna Benet-Pagès; Walter Struhal; Elisabeth Graf; Sebastian H. Eck; Marc N. Offman; Dietrich Haubenberger; Sabine Spielberger; Eva C. Schulte; Peter Lichtner; Shaila C. Rossle; Norman Klopp; Elisabeth Wolf; Klaus Seppi; Walter Pirker; Stefan Presslauer; Brit Mollenhauer; Regina Katzenschlager; Thomas Foki; Christoph Hotzy; Eva Reinthaler; Ashot S. Harutyunyan; Robert Kralovics; Annette Peters; Fritz Zimprich; Thomas Brücke; Werner Poewe; Eduard Auff; Claudia Trenkwalder; Burkhard Rost
To identify rare causal variants in late-onset Parkinson disease (PD), we investigated an Austrian family with 16 affected individuals by exome sequencing. We found a missense mutation, c.1858G>A (p.Asp620Asn), in the VPS35 gene in all seven affected family members who are alive. By screening additional PD cases, we saw the same variant cosegregating with the disease in an autosomal-dominant mode with high but incomplete penetrance in two further families with five and ten affected members, respectively. The mean age of onset in the affected individuals was 53 years. Genotyping showed that the shared haplotype extends across 65 kilobases around VPS35. Screening the entire VPS35 coding sequence in an additional 860 cases and 1014 controls revealed six further nonsynonymous missense variants. Three were only present in cases, two were only present in controls, and one was present in cases and controls. The familial mutation p.Asp620Asn and a further variant, c.1570C>T (p.Arg524Trp), detected in a sporadic PD case were predicted to be damaging by sequence-based and molecular-dynamics analyses. VPS35 is a component of the retromer complex and mediates retrograde transport between endosomes and the trans-Golgi network, and it has recently been found to be involved in Alzheimer disease.
Nature Genetics | 2009
Hreinn Stefansson; Stacy Steinberg; Hjorvar Petursson; Omar Gustafsson; Iris H Gudjonsdottir; Gudrun A Jonsdottir; Stefan Palsson; Thorlakur Jonsson; Jona Saemundsdottir; Gyda Bjornsdottir; Yvonne Böttcher; Theodora Thorlacius; Dietrich Haubenberger; Alexander Zimprich; Eduard Auff; Christoph Hotzy; Claudia M. Testa; Lisa A Miyatake; Ami Rosen; Kristleifur Kristleifsson; David B. Rye; Friedrich Asmus; Ludger Schöls; Martin Dichgans; Finnbogi Jakobsson; John Benedikz; Unnur Thorsteinsdottir; Jeffrey R. Gulcher; Augustine Kong; Kari Stefansson
We identified a marker in LINGO1 showing genome-wide significant association (P = 1.2 x 10(-9), odds ratio = 1.55) with essential tremor. LINGO1 has potent, negative regulatory influences on neuronal survival and is also important in regulating both central-nervous-system axon regeneration and oligodendrocyte maturation. Increased axon integrity observed in Lingo1 mouse [corrected] knockout models highlights the potential role of LINGO1 in the pathophysiology of ET [corrected]We identified a marker in LINGO1 showing genome-wide significant association (P = 1.2 × 10−9, odds ratio = 1.55) with essential tremor. LINGO1 has potent, negative regulatory influences on neuronal survival and is also important in regulating both central-nervous-system axon regeneration and oligodendrocyte maturation. Increased axon integrity observed in Lingo1 mouse knockout models highlights the potential role of LINGO1 in the pathophysiology of essential tremor.
Neurology | 2006
Elisabeth Stogmann; Peter Lichtner; Christoph Baumgartner; S Bonelli; Eva Assem-Hilger; Fritz Leutmezer; Mascha C. Schmied; Christoph Hotzy; Tim M. Strom; Thomas Meitinger; Fritz Zimprich; Alexander Zimprich
We sequenced 61 patients with various idiopathic generalized epilepsy (IGE) syndromes for mutations in the EFHC1 gene. We detected three novel heterozygous missense mutations (I174V, C259Y, A394S) and one possibly pathogenic variant in the 3′ UTR (2014t>c). The mutation I174V was also detected in 1 of 372 screened patients with temporal lobe epilepsy. We conclude that mutations in the EFHC1 gene may underlie different types of epilepsy syndromes.
Neurology | 2009
Kurt Schlachter; Ursula Gruber-Sedlmayr; Elisabeth Stogmann; M. Lausecker; Christoph Hotzy; Jörg Balzar; Elisabeth Schuh; Christoph Baumgartner; Jakob C. Mueller; Thomas Illig; H-Erich Wichmann; Peter Lichtner; Thomas Meitinger; Tim M. Strom; Alexander Zimprich; Fritz Zimprich
Objective: Our aim was to investigate whether the risk of febrile seizures is influenced by a common functional polymorphism in the sodium channel gene SCN1A. This single nucleotide polymorphism (IVS5N+5 G>A, rs3812718) was shown to modify the proportion of two alternative transcripts of the channel. Methods: We performed an exploratory case–control association analysis in 90 adult epilepsy patients with childhood febrile seizures vs 486 epilepsy patients without a history of febrile seizures and also vs 701 population controls. In the replication step, we investigated children with febrile seizures without concomitant epilepsy at the time of their inclusion. We compared the genotypes of 55 of those children against population controls and performed a within-family association analysis in an additional 88 child–parent trios with febrile seizures. Results: We observed a significant association of the splice-site interrupting A-allele with febrile seizures (p value in the exploratory step: 0.000017; joint p value of the replication: 0.00069). Our data suggest that the A-allele of this variant confers a threefold genotype relative risk in homozygotes and accounts for a population attributable fraction of up to 50% for the etiology of febrile seizures. Conclusions: The A-allele of the SCN1A single nucleotide polymorphism IVS5N+5 G>A (rs3812718) represents a common and relevant risk factor for febrile seizures. A limitation of the present study is that patients of the exploratory and replication steps differed in aspects of their phenotype (febrile seizures with and without additional epilepsy).
Annals of Neurology | 2015
Eva M. Reinthaler; Borislav Dejanovic; Dennis Lal; Marcus Semtner; Yvonne Merkler; Annika Reinhold; Dorothea A. Pittrich; Christoph Hotzy; Martha Feucht; Hannelore Steinböck; Ursula Gruber-Sedlmayr; Gabriel M. Ronen; Birgit Neophytou; Julia Geldner; Edda Haberlandt; Hiltrud Muhle; M. Arfan Ikram; Cornelia M. van Duijn; André G. Uitterlinden; Albert Hofman; Janine Altmüller; Mohammad R. Toliat; Peter Nürnberg; Holger Lerche; Michael Nothnagel; Holger Thiele; Thomas Sander; Jochen C. Meier; Günter Schwarz; Bernd A. Neubauer
To test whether mutations in γ‐aminobutyric acid type A receptor (GABAA‐R) subunit genes contribute to the etiology of rolandic epilepsy (RE) or its atypical variants (ARE).
Pharmacogenomics | 2012
Eva Hilger; Eva M. Reinthaler; Elisabeth Stogmann; Christoph Hotzy; Ekaterina Pataraia; Christoph Baumgartner; Alexander Zimprich; Fritz Zimprich
AIM The aim of this study was to replicate a previously reported association between drug resistance in epilepsy patients and the 24C>T variant of the ABCC2 gene that codes for the drug efflux transporter MRP2. PATIENTS & METHODS We genotyped 381 Caucasian epileptic patients (337 drug resistant and 44 drug responsive) and 247 healthy controls for the ABCC2 gene -24C>T polymorphism (rs717620) and two other nearby SNPs in linkage disequilibrium (1249G>A and 3972C>T). Genotype, allele and three-SNP-haplotype frequencies were compared between groups. Patients were further stratified into four groups according to their degree of drug resistance (as measured by seizure frequency under medication) to perform regression analysis against genotypes and haplotpyes. RESULTS We detected no significant differences in the distribution of any of the tested alleles, genotypes or haplotypes between the investigated groups. Neither was there an association between genotypes or haplotypes and degree of drug resistance. This study was adequately powered to detect genotype relative risks of above two. CONCLUSION Although adequately powered to detect the previously reported effect size and although our definition of drug resistance, following the International League Against Epilepsy guidelines, was slightly stricter than in the original study, we failed to confirm an association between the 24C>T variant in the ABCC2 gene and drug resistance in epilepsy.
Movement Disorders | 2009
Dietrich Haubenberger; Christoph Hotzy; Walter Pirker; Regina Katzenschlager; Thomas Brücke; Fritz Zimprich; Eduard Auff; Alexander Zimprich
A clinical overlap between Parkinsons disease (PD) and essential tremor (ET) has prompted a discussion whether these conditions share common genetic susceptibility factors. Recently, the first genome‐wide association study in ET revealed a significant association with a variant in the LINGO1 gene. LINGO1 has also been demonstrated to play a role in the survival of dopaminergic neurons in an animal model of PD, and therefore constitutes a potential candidate gene for PD. In this study, SNPs rs9652490, rs11856808, and rs7177008 of LINGO1 were genotyped in a total of 694 Austrian subjects (349 PD, 345 controls). No association could be found between genotype or allele counts and PD. Neither did a subgroup analysis in tremor‐dominant patients with PD reveal a significant association. This study on LINGO1‐variants in PD argues against a major role of LINGO1 gene variations for PD.
Neurogenetics | 2006
Elisabeth Stogmann; Peter Lichtner; Christoph Baumgartner; Mascha C. Schmied; Christoph Hotzy; F. Asmus; Fritz Leutmezer; S Bonelli; Eva Assem-Hilger; Karl Vass; K. Hatala; Tim M. Strom; Thomas Meitinger; Fritz Zimprich; Alexander Zimprich
Mutations in the chloride channel gene CLCN2 have been reported in families with generalized and focal epilepsy syndromes. To evaluate the contribution of mutations in the CLCN2 gene to the etiology of epilepsies in our population, we screened 96 patients with different epilepsy syndromes and a putative genetic background. No definite mutations were found in our study population. We conclude that mutations in the CLCN2 gene are only a rare cause of idiopathic generalized epilepsy.
Movement Disorders | 2007
Dietrich Haubenberger; S Bonelli; Christoph Hotzy; Petra Leitner; Peter Lichtner; Doris Samal; Regina Katzenschlager; Atbin Djamshidian; Thomas Brücke; Michaela Steffelbauer; Christian Bancher; Josef Grossmann; Gerhard Ransmayr; Tim M. Strom; Thomas Meitinger; Thomas Gasser; Eduard Auff; Alexander Zimprich
To investigate the frequency of mutations in the Leucine‐Rich Repeat Kinase 2 gene (LRRK2) in a sample of Austrian Parkinsons disease (PD) patients, we sequenced the complete coding region in 16 patients with autosomal dominant PD. Furthermore, we sequenced exons 31, 35, and 41 additionally in 146 patients with idiopathic PD and 30 patients with dementia with Lewy bodies. Furthermore, all 192 patients were screened for 21 putative LRRK2 mutations. While the most common mutation G2019S and the risk variant G2385R were not found in our samples, we detected a novel missense mutation (S973N) in a patient with familial, late‐onset and dopa‐responsive PD.
Neurogenetics | 2012
Mascha C. Schmied; Sonja Zehetmayer; Markus Reindl; Rainer Ehling; Barbara Bajer-Kornek; Fritz Leutmezer; Karin Zebenholzer; Christoph Hotzy; Peter Lichtner; Thomas Meitinger; H-Erich Wichmann; Thomas Illig; Christian Gieger; Klaus Huber; Michael Khalil; S Fuchs; Helena Schmidt; Eduard Auff; Wolfgang Kristoferitsch; Franz Fazekas; Thomas Berger; Karl Vass; Alexander Zimprich
We performed a replication study in 883 Austrian multiple sclerosis (MS) patients and 972 control individuals for 25 previously risk-associated loci (39 SNPs). Two loci, rs1109670 (DDEF2/MBOAT2, p < 0.02) and rs16914086 (TBC1D2, p < 0.05), are replicated here for the first time. Furthermore, we tested all 39 SNPs for association with age at disease onset and measures of disease severity. We observed a trend for association of rs3135388 (HLA-DRB1*1501, p < 0.01), rs7090530 (IL2RA, p < 0.026) and rs1841770 (ZIC1, p < 0.017) with a younger age at MS onset and of rs12044852 (CD58, p < 0.035) with shorter time to reach EDSS6.